[go: up one dir, main page]

LT3882250T - Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui - Google Patents

Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui

Info

Publication number
LT3882250T
LT3882250T LTEP21165852.1T LT21165852T LT3882250T LT 3882250 T LT3882250 T LT 3882250T LT 21165852 T LT21165852 T LT 21165852T LT 3882250 T LT3882250 T LT 3882250T
Authority
LT
Lithuania
Prior art keywords
tetrahydropyranilamino
pyrolopyrimidinone
btk
treatment
disorders caused
Prior art date
Application number
LTEP21165852.1T
Other languages
English (en)
Inventor
Jean-Marc Lapierre
Sudharshan Eathiraj
Nivedita Namdev
Brian Schwartz
Yusuke Ota
Takayuki Momose
Tomoyuki Tsunemi
Hiroaki Inagaki
Kiyoshi Nakayama
Original Assignee
Arqule, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule, Inc. filed Critical Arqule, Inc.
Publication of LT3882250T publication Critical patent/LT3882250T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP21165852.1T 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui LT3882250T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2015/000285 WO2017111787A1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP21165852.1A EP3882250B1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone for use in treating btk-mediated disorders

Publications (1)

Publication Number Publication Date
LT3882250T true LT3882250T (lt) 2023-05-25

Family

ID=59090991

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP21165852.1T LT3882250T (lt) 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
LTEP15911490.9T LT3394065T (lt) 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP15911490.9T LT3394065T (lt) 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai

Country Status (28)

Country Link
EP (2) EP3394065B1 (lt)
JP (1) JP6634520B2 (lt)
KR (2) KR102547188B1 (lt)
CN (2) CN113307811B (lt)
AU (3) AU2015417922B2 (lt)
CA (1) CA3008446C (lt)
CY (1) CY1124210T1 (lt)
DK (2) DK3882250T3 (lt)
ES (2) ES2942743T3 (lt)
FI (1) FI3882250T3 (lt)
HR (2) HRP20230379T1 (lt)
HU (2) HUE055221T2 (lt)
IL (2) IL259938B (lt)
LT (2) LT3882250T (lt)
MA (1) MA56553B1 (lt)
MD (1) MD3882250T2 (lt)
MX (1) MX2018007815A (lt)
MY (1) MY193177A (lt)
PH (1) PH12018501390B1 (lt)
PL (2) PL3882250T3 (lt)
PT (2) PT3394065T (lt)
RS (2) RS61887B1 (lt)
RU (1) RU2715421C2 (lt)
SA (1) SA518391836B1 (lt)
SG (1) SG11201805154YA (lt)
SI (2) SI3394065T1 (lt)
WO (1) WO2017111787A1 (lt)
ZA (1) ZA201804091B (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
JP7535537B2 (ja) * 2019-05-31 2024-08-16 フォチョン・バイオサイエンシーズ・リミテッド タンパク質キナーゼ阻害剤としての置換ピロロ[2,3-b]ピリジン及びピラゾロ[3,4-b]ピリジン誘導体
EP4059935A4 (en) * 2019-11-13 2024-02-28 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. PYRROLOPYRIMIDINE COMPOUND AS BTK INHIBITOR AND USE THEREOF
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
JP7011638B2 (ja) * 2019-12-16 2022-02-10 アークル インコーポレイテッド テトラヒドロピラニルアミノ-ピロロピリミジノンおよびその使用の方法
JP2023549273A (ja) * 2020-11-17 2023-11-22 フォチョン・バイオサイエンシーズ・リミテッド プロテインキナ-ゼ阻害剤としての置換されたピロロ[2,3-b]ピリジン及びピラゾロ[3,4-b]ピリジン誘導体
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技(苏州)有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
WO2022213932A1 (zh) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
EP4339198A1 (en) * 2021-05-12 2024-03-20 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. Crystal form of pyrrolopyrimidine compound and preparation method for crystal form
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715A (zh) * 2023-04-06 2023-07-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2013511541A (ja) * 2009-11-18 2013-04-04 プレキシコン インコーポレーテッド キナーゼ調節のための化合物および方法、ならびにその適応
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
TW201522337A (zh) * 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並-嘧啶化合物類
WO2014152114A1 (en) * 2013-03-15 2014-09-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds

Also Published As

Publication number Publication date
WO2017111787A1 (en) 2017-06-29
EP3882250A1 (en) 2021-09-22
MX2018007815A (es) 2019-07-04
SG11201805154YA (en) 2018-07-30
SI3394065T1 (sl) 2021-08-31
AU2015417922B2 (en) 2018-12-20
RS61887B1 (sr) 2021-06-30
EP3394065A1 (en) 2018-10-31
RS64141B1 (sr) 2023-05-31
IL282572A (en) 2021-06-30
ES2868884T3 (es) 2021-10-22
KR20230098690A (ko) 2023-07-04
EP3394065A4 (en) 2019-07-10
PT3394065T (pt) 2021-05-06
MY193177A (en) 2022-09-26
JP2018538349A (ja) 2018-12-27
MA56553B1 (fr) 2023-04-28
ES2942743T3 (es) 2023-06-06
LT3394065T (lt) 2021-06-25
PL3394065T3 (pl) 2021-08-02
AU2019201737A1 (en) 2019-04-04
CN108699062B (zh) 2021-06-29
PT3882250T (pt) 2023-04-21
AU2015417922A1 (en) 2018-06-28
HUE055221T2 (hu) 2021-11-29
CN113307811A (zh) 2021-08-27
ZA201804091B (en) 2019-03-27
HRP20210844T1 (hr) 2021-07-09
IL282572B (en) 2022-04-01
MA56553A (fr) 2022-04-27
RU2018126793A3 (lt) 2020-01-23
IL259938A (en) 2018-07-31
RU2715421C2 (ru) 2020-02-28
FI3882250T3 (fi) 2023-04-27
DK3394065T3 (da) 2021-05-31
CY1124210T1 (el) 2022-05-27
PL3882250T3 (pl) 2023-09-11
JP6634520B2 (ja) 2020-01-22
KR102746900B1 (ko) 2024-12-24
AU2019201737B2 (en) 2020-03-05
SI3882250T1 (sl) 2023-07-31
MD3882250T2 (ro) 2023-06-30
PH12018501390B1 (en) 2022-06-10
CN108699062A (zh) 2018-10-23
EP3882250B1 (en) 2023-02-15
AU2020203690B2 (en) 2021-08-05
AU2020203690A1 (en) 2020-06-25
BR112018012828A2 (pt) 2018-12-04
KR102547188B1 (ko) 2023-06-26
EP3394065B1 (en) 2021-04-07
DK3882250T3 (da) 2023-05-22
CA3008446A1 (en) 2017-06-29
SA518391836B1 (ar) 2022-06-19
HRP20230379T1 (hr) 2023-06-23
RU2018126793A (ru) 2020-01-23
NZ743384A (en) 2024-05-31
KR20180096753A (ko) 2018-08-29
CA3008446C (en) 2023-10-10
PH12018501390A1 (en) 2019-02-27
CN113307811B (zh) 2023-11-14
IL259938B (en) 2021-05-31
HUE061761T2 (hu) 2023-08-28

Similar Documents

Publication Publication Date Title
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
CY2024015I2 (el) Ρυθμιση δραστικοτητας συμπληρωματος
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
DK3230281T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
IL247452A0 (en) Compounds for treatment of complement mediated disorders
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
LT3159409T (lt) Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui
DK3231444T3 (da) Ny behandling
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
DK3104854T3 (da) Mast-celle-stabilisatorer til lungesygdomsbehandling
LT3494962T (lt) Skysta inhaliavimo kompozicija, apimanti rpl554
HUE053376T2 (hu) Poliuretánok elõállításában történõ alkalmazásra megfelelõ, nitrogént tartalmazó vegyületek
EP3209331C0 (en) EYE SOLUTION
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3203834T3 (da) Hovbehandlingsarrangement
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3166473T3 (da) Oftalmoskoper
DK3122763T3 (da) Antimikrobielle peptiddendrimerer
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK3302478T3 (da) Pac-1 kombinations behandling
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme